A new Sunlight survey of 1,000 U.S. peptide users finds that gray-market buyers visit the ER at 3x the rate of all peptide users. Three in four of these buyers have told their doctor about their peptide use, but the doctor never sees what was bought on social media.
New direct-to-consumer site provides physician-reviewed access to compounded semaglutide and tirzepatide, delivered to patients’ doors.
Better Care Services platform connects customers to virtual care and nutrition support, complementing fast, convenient access to medications through Walmart’s nationwide pharmacy network.
Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary.
The most effective GLP-1 medication is now available in a multi-dose pen.
This approval for Wegovy further expands its already robust label inclusive of multiple formulations, including Wegovy pill, and indications not available with other GLP-1 weight loss medicines.
GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs.
Customers filling their first GLP1 prescription at a ShopRite Pharmacy will receive a complimentary kit while supplies last.
As part of a 5‑month plan, introductory pricing begins at $49 for the first month.
Vida’s Self-Pay (Powered by RxSaveCard) leverages a flexible proprietary payment platform to expand affordable access to obesity treatment.
The 1.5 mg pill is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.
Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation.
Wegovy pill now broadly available through over 70,000 US pharmacies such as CVS and Costco.
This shift directly impacts purchasing decisions, with consumers altering their baskets to align with new dietary preferences.
Internationally recognized researcher in medical safety and privacy, former Chief Scientist and CIO at the FDA, brings scientific and regulatory leadership to Shotsy.
The company aims to make FDA approved semaglutide therapies safer and more financially accessible, compared to compounded weight-loss alternatives.
